Citi lowered the firm’s price target on QuidelOrtho (QDEL) to $40 from $50 and keeps a Buy rating on the shares. The firm views the company’s Q2 report and cost actions planned for the back of half of 2025 positively.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL: